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Abstract
The resolution of the three-dimensional structure of infectious prions at the atomic level is
pivotal to understand the pathobiology of Transmissible Spongiform Encephalopathies
(TSE), but has been long hindered due to certain particularities of these proteinaceous path-
ogens. Difficulties related to their purification from brain homogenates of disease-affected
animals were resolved almost a decade ago by the development of in vitro recombinant
prion propagation systems giving rise to highly infectious recombinant prions. However, lack
of knowledge about the molecular mechanisms of the misfolding event and the complexity
of systems such as the Protein Misfolding Cyclic Amplification (PMCA), have limited gener-
ating the large amounts of homogeneous recombinant prion preparations required for high-
resolution techniques such as solid state Nuclear Magnetic Resonance (ssNMR) imaging.
Herein, we present a novel recombinant prion propagation system based on PMCA that
substitutes sonication with shaking thereby allowing the production of unprecedented
amounts of multi-labeled, infectious recombinant prions. The use of specific cofactors, such
as dextran sulfate, limit the structural heterogeneity of the in vitro propagated prions and
makes possible, for the first time, the generation of infectious and likely homogeneous
samples in sufficient quantities for studies with high-resolution structural techniques as
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demonstrated by the preliminary ssNMR spectrum presented here. Overall, we consider
that this new method named Protein Misfolding Shaking Amplification (PMSA), opens new
avenues to finally elucidate the three-dimensional structure of infectious prions.
Author summary
Prion disorders are a group of devastating neurodegenerative diseases caused by an aber-
rantly folded isoform of the endogenous prion protein. The molecular mechanisms by
which this proteinaceous pathogen is able to propagate in the central nervous system and
cause neuronal death are poorly understood, partially due to the difficulties elucidating
the three-dimensional structure of the aggregation-prone aberrant isoform or prion.
Obtaining sufficient amounts of highly pure and homogeneous prions for high-resolution
structural studies has been limited until now due to technical reasons. Here, we present a
novel method for the production of large amounts of highly infectious recombinant pri-
ons suitable for solid state Nuclear Magnetic Resonance imaging, which could help to
unveil the molecular pathogenesis of these particular pathogens.
Introduction
The generation of recombinant prions in vitro able to cause Transmissible Spongiform
Encephalopathy (TSE) in vivo has been one of the greatest advances of the last decades in the
field [1–12] and has been successfully achieved by several research groups, although there are
still several unsolved issues that make this process of particular interest: 1) The recombinant
prions generated by different research groups applying similar techniques yielded highly vari-
able results. From generating prions with infectivity similar to that of some mammalian prions
[8, 10], to producing prions with very low infectious ability or even lacking infectivity in vivo,
requiring in some cases multiple in vivo passages to cause clinical prion disease [1–3, 6]. 2) It is
unknown whether any other component, besides PrPSc, may be the infectious particle. Many
different molecules have been tested (RNA, lipids, dextran sulfate, plasmid, etc.) and, in some
cases, those are claimed as a requirement for in vitro infectious prion formation [4, 8, 13–15],
however, credible evidence is lacking. There are several methods capable of generating mis-
folded self-propagating recombinant PrP but given the disparity of infective abilities, it is
impossible to clarify which is the best to generate infectious recombinant prions and which
may yield only non-infectious misfolded recombinant PrPs. 3) Finally, these techniques could
help to determine the critical difference between infectious and non-infectious self-propagat-
ing, protease-resistant misfolded recombinant PrPs.
The vast majority of studies for in vitro recombinant prion generation have been performed
using PrPs from well-known rodent species, mainly mouse (Mus musculus) [1, 8] and hamster
(Mesocricetus auratus) [5]. Both are some of the best-characterized models of TSE and are the
preferred ones for evaluating in vivo infectivity due to short incubation period and ease of han-
dling. Recently, another rodent species, bank vole (Myodes glareolus) has become increasingly
popular due to its particular attributes. A polymorphic variant of the bank vole PrP, bearing
isoleucine at position 109, shows the ability to misfold spontaneously in vitro [10] and its over-
expression in transgenic mice leads to a spontaneous and transmissible prion disease [16]. The
bank vole is also considered to be an almost universal acceptor of prions since can be infected
with a large diversity of prion strains from different donor species [17] and when infected with
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Chronic Wasting Disease (CWD), a TSE from cervids, has the shortest incubation period of
any known prion disease [18].
This combination of bank vole-based rodent models and the development of new genera-
tion recombinant prion propagation systems may finally decipher the mechanisms of infectiv-
ity of prions and may allow elucidation of the different structural features of various prion
strains. The generation of the first highly infectious recombinant prion, using recombinant
mouse PrP complemented with RNA and lipids, resulted in spontaneous misfolding of the
protein using protein misfolding cyclic amplification (PMCA) [8]. This proved that prions
able to cause clinical disease in vivo could be generated in vitro with minimal synthetic compo-
nents. The presence of lipids and RNA in the mixture and previous research claiming the need
of cofactors for the generation of infectious recombinant prions [12, 14, 15, 19–21] suggested
that recombinant PrP alone was not sufficient to give rise to infectious prions in vitro. How-
ever, the actual role of cofactors was never investigated further so the true characteristics of
prion infectivity remain unknown.
Recently, infectious recombinant prions have been generated in the absence of cofactors
using PMCA and recombinant PrPs as the reaction substrate [10]. Recombinant bank vole
I109 prions were generated by two distinct procedures: spontaneously and using a seed based
on infectious prions of mammalian origin [18]. Several distinct infectious recombinant prion
strains were generated in both ways using a variety of substrates containing different cofactors:
from complete brain homogenates of PrP knock-out transgenic mice (Prnp0/0) to substrates
containing cofactors such as RNA, dextran sulfate or plasmid DNA, or in the absence of any
cofactor. Among the conclusions derived from this research is that, in a cofactor rich environ-
ment (i.e. PrP and Prnp0/0 brain homogenate), the recombinant PrP misfolds in many different
conformations, giving rise to a mixture of strains with distinct properties regarding their elec-
trophoretic migration patterns and their abilities to cause disease in vivo. This is in agreement
with recent studies on prion strain evolution that propose the existence of pools of slightly dif-
ferent prion conformers called prion substrains or quasispecies [22–24]. Our previous work,
in which substrates with minimal components (i.e. dextran sulfate, RNA and plasmid DNA)
were proven useful to select or specifically propagate certain strains [10], highlighted the possi-
bility of generating more homogeneous samples that could facilitate the application of ssNMR
to infectious prions. Although the selection of a single strain could not be definitively demon-
strated, our results clearly indicated that using selective substrates, the conformer variety of the
original seed could be reduced.
To understand the nature of prion infectivity, which would allow us to understand the
nature of different prion strains, knowledge of the three dimensional structure of different pri-
ons at the atomic level appears necessary [25]. Techniques such as Hydrogen/Deuterium
exchange [26–28], limited proteolysis coupled to mass spectrometry [29–33] and electron
microscopy [34, 35] have been used for that purpose and the information obtained from them
was highly valuable although insufficient to definitively understand the essence of prion infec-
tivity. The incomplete knowledge about prion structural features is obvious considering the
radically distinct structural models currently proposed for prions [34, 36, 37], both based on
different techniques. The limited success of the aforementioned techniques and the constraints
imposed by infectious prions, which are intrinsically aggregated making them unsuitable for
high resolution techniques such as X-ray crystallography or nuclear magnetic resonance
(NMR) imaging, reduces the possibilities of determining the atomic structure of infectious pri-
ons except by techniques such as solid state NMR (ssNMR) [38]. This technique has already
resolved the structures of proteins with similar properties to mammalian prions like HET-S
[39], Aβ amyloid [40] and even a synthetic infectious PrP23-144 amyloid that seems to propa-
gate in vivo by templating endogenous PrPC into PrPSc [41]. Despite its potential, ssNMR has
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only been successfully applied to the resolution of a single truncated mammalian prion struc-
ture [42] due to two main limitations as it requires: 1) significant homogeneity of the sample
under study and, 2) large amounts of isotopically labeled material.
Here, we present a new technique for propagation in vitro of infectious recombinant prions
that overcomes the limitation of generating large amounts of isotopically labeled sample
required for ssNMR studies. The procedure is based on PMCA, from where the misfolded
recombinant seed is obtained. This infectious seed has been adapted to a new system in which
shaking [43] is used instead of sonication for in vitro propagation of recombinant prions and
this novel propagation method has been named Protein Misfolding Shaking Amplification
(PMSA). This methodology eliminates the need of complex and expensive equipment permit-
ting its implementation in any basic laboratory and allows the generation of 2.5 mg of prote-
ase-K digested infectious recombinant prion per day ready to be studied. The optimization
applied to PMSA permits greater than 1,000-fold scaling up from minute amounts of seed of
isotopically labeled material (and also multiple labeling) suitable for ssNMR studies, as shown
by the preliminary spectrum presented here.
Results
Selection of an infectious recombinant prion for ease of indefinite in vitro
propagation
With ssNMR studies in mind, a recombinant misfolded PrP was selected that fulfilled the fol-
lowing ideal characteristics: 1) minimal additional components required to be propagated in
vitro, 2) additional components cheap and easily obtainable, 3) highly permissible to in vitro
propagation allowing rapid generation of large amounts, and 4) infectious in vivo (100% attack
rate with reasonable incubation times using a wild-type or no overexpression model).
In a previous study, a recombinant bank vole PrP complemented with Prnp0/0 mouse brain
homogenate (to provide any cofactor from the brain that may be required) was misfolded by
PMCA (named H/L-seeded-03). The resultant strain mixture could be selected or adapted to
different in vitro propagation environments in which the Prnp0/0 brain homogenate was
replaced by single cofactor complemented substrate such as dextran sulfate or RNA [10]. The
latter recombinant seeds, requiring minimal additional components, were infectious in vivo,
resulted in classical electrophoretic migration patterns and were more homogeneous than those
complemented with brain homogenate, in which strain mixtures were detected upon in vivo
inoculation [10]. Among these, the dextran-complemented recombinant prion (from now on
named L-seeded-PMCA) resulted in slightly higher attack rates and much shorter incubation
times, as well as a better in vitro propagation capacity [10]. Therefore, the recombinant bank
vole seed generated in Prnp0/0 brain homogenate and adapted to dextran-complemented sub-
strate by serial PMCA rounds was chosen as the most suitable prion to adapt to PMSA.
Adaptation of the chosen recombinant prion to the new PMSA method
PMSA was developed based on PMCA, but seeking increased product output. Its success lies
on propagating at least 1,000 times larger volumes of misfolded recombinant PrP, from the
hundreds of microliters that can be propagated by PMCA (space limited by plate sonicators)
to hundreds of millilitres, avoiding the use of complex or expensive equipment.
Therefore, the first step consisted on designing a method avoiding sonication, but efficient
enough propagating the seed of choice. To address this, all the parameters used in PMCA for
recombinant prion propagation (i. e. temperature, incubation times, number of propagation
rounds) were retained except the quantity limiting sonication, which was substituted with
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shaking. Standard shakers with appropriate temperature control would allow development of
a highly scalable method by designing specific racks for tubes of any size allowing the produc-
tion of the volumes required for structural studies. The L-seeded-PMCA recombinant seed, of
proven infectivity and showing distinctive strain features [10], was propagated serially for 40
rounds at 1:10 dilution over a substrate containing bank vole recombinant PrP with dextran
sulfate in order to adapt it to PMSA (named L-seeded-PMSA). Its stability through the serial
rounds was checked and compared to the PMCA-derived prion also. Both the electrophoretic
patterns (Fig 1A and 1B), as well as the abilities to propagate by PMCA in whole brain homog-
enate substrates (indicator of their potential in vivo infectivity), were conserved suggesting
adaptation to PMSA (Fig 1C).
Once the seed was adapted to serial propagation in the novel system, the propagative abili-
ties of both methods were compared by performing a serial dilution of each seed over a single
round of PMCA or PMSA (Fig 2). Both seeds showed a similar propagation capacity after
applying both methodologies. Dilutions of 104−105 could be detected by WB after PK treat-
ment, a reasonable dilution but suggesting the need for optimization.
Optimization
To improve the propagative capacity of the PMSA, all parameters possibly relevant for PrP
misfolding were considered and the propagation ability evaluated by serial dilution of the seed
in a variety of conditions. Optimisation of the parameters for recombinant prion propagation
was performed using three different shakers. Two different shakers with thermoblocks (Ther-
momixer from Eppendorf and a digital heating shaking drybath from Thermo-Scientific) and
a simple plate shaker without temperature control placed in an oven to control temperature.
The outcome of each parameter-variation was evaluated by Thioflavin T measurement and by
proteinase K digestion and Western blotting as detailed in Materials and methods. The initial
parameters set for PMSA were an adaptation of our regular recombinant PMCA settings.
Recombinant protein concentration (2 μM) and PMCA substrate preparation were conserved
as well as the temperature (38˚C), addition of 1 mm zirconia/silica beads and 24 h propagation
rounds. As the energy provided by the system is presumably lower than by sonication, the
maximum speed of the shakers (1,200 rpm) was used and to increase shaking cycles with
respect to PMCA, cycles of 60 s shaking and 5 min incubation were used. However, all parame-
ters were modified to optimize the propagation capacity evaluated by serial dilution of the
recombinant seed in a range of different parameters. Shaking speed, shaking/incubation
cycles, type of beads, temperature and rec-PrP concentration were optimized. Optimal condi-
tions were found to be shaking at 1,000 rpm continuously, with 1.0 mm zirconium silicate
beads at 39˚C and 2 μM of rec-PrP (Fig 3).
Scalability of PMSA
Once the propagation parameters were optimized, the scalability and repeatability of the novel
method needed to be assessed. A serial dilution study was performed using tubes of different
size with specific adaptors, designed by 3D printing, for each of them (Supplementary infor-
mation, S1 Fig). PCR tubes (volume 50 μl), 2 ml tubes (volume 1 ml) and 5 ml tubes (volume
4.5 ml) were tested, as the scalability levels demanded to the system required tubes where large
volumes could be propagated. In all the cases, 1 mm zirconium silicate beads were added and
the tube orientated to favour bead movement. Propagation capacities were compared by serial
dilutions of the seed as described previously.
Propagation was most and equally efficient in the 2 and 5 ml tubes, although all tube sizes
resulted in reasonable propagative capacity. Thus, 2 and 5 ml tubes, apart from being the best
A largely scalable new method to produce infectious recombinant prions
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vessels to reach the amounts of misfolded protein required (Fig 4) are easier to handle than the
smaller ones and with just one standard shaker and oven allowed the generation of milligrams
of misfolded sample per day (with 10 shakers, up to 400 ml can be produced daily).
Fig 1. Adaptation of the infectious recombinant prion (L-seeded-PMCA) to the new in vitro propagation method
(L-seeded-PMSA). A) Immunodetection of the characteristic protease resistant core resulting from cleavage of the
amino-terminal tail of the original PMCA-derived recombinant prions (H/L-seeded-03 and L-seeded-PMCA) and the
PMSA-adapted one (L-seeded-PMSA) by Western blotting. Samples were digested with 85 μg/ml of proteinase-K (PK)
and analyzed by Western blotting using monoclonal antibodies 12B2 (1:2,500) and D18 (1:5,000). Differential
digestion of the N-terminal makes the two recombinant prions adapted to propagate in dextran sulfate-complemented
substrates (L-seeded-PMCA and L-seeded-PMSA) undetectable by 12B2 mAb (epitope 88–92) whereas the Prnp0/0-
complemented sample (H/L-seeded-03), which according to previous results (10) is a mixture of strains, detectable by
both 12B2 and D18 mAbs (epitope 143–149). B) Electrophoretic migration patterns of L-seeded-PMCA and L-seeded-
PMSA recombinant prions. The two recombinant prions were digested with PK and analyzed by BlueSafe staining
(total protein) to examine all the proteolytic fragments derived from digestion. The same gel was transferred for
Western blotting and developed with D18 mAb. Both recombinant misfolded PrPs show a similar banding pattern,
suggesting similar if not identical conformations. The differences on electrophoretic patterns detected by D18 antibody
between the gel in panel A and the one in panel B are due to the amount of sample loaded in each case. For total
protein staining and posterior western blotting from panel B, 50x more sample is loaded than for panel A, making
some minor PrP fragments detectable. C) Determination of potential infectivity (ability to propagate on brain-derived
PrP) of L-seeded-PMCA and L-seeded-PMSA recombinant prions by brain-PMCA. Conservation of the capacity to
misfold brain-derived PrPC, as an indication of potential in vivo infectivity, was evaluated using equal amounts of the
two recombinant inocula as seeds in TgVole brain homogenate at 1:10 dilution during one round of PMCA.
Triplicates (T1, T2 & T3) were performed for both samples and PK-resistant PrP formation was monitored by Western
blotting with D18 mAb. Misfolded brain-derived PrP arises from the first round for the dextran sulfate-complemented
seeds with no difference between PMCA- or PMSA-adapted seeds (L-seeded-PMCA and L-seeded-PMSA). (!)
Signals of PK-digested misfolded rec-PrPs appear lower than those of the non-glycosylated band due to the absence of
the GPI anchor. rec-PrP (control): undigested bank vole rec-PrP protein. Brain (control): undigested TgVole whole
brain homogenate. NA: Non-amplified samples.
https://doi.org/10.1371/journal.ppat.1008117.g001
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In vitro propagation efficiency
To estimate the efficiency of prion propagation by PMSA, the formation of protein aggregates
that could be pelleted by centrifugation was undertaken. Since infectious PK-sensitive aggre-
gates have also been described [31], the quantification of only protease-resistant misfolded PrP
was considered inaccurate. However, the formation of amorphous aggregates without infec-
tious capacity, which may also be protease sensitive, needs to be taken into account for the
quantification of infectious prion formation in vitro. For that, unseeded and seeded (1: 100,000
dilution) substrates were submitted to a 24 h PMSA round taking samples at several time
points. The soluble rec-PrP in the supernatant of the seeded sample was not detectable after 2
h (Fig 5A), indicating all PrP from the substrate had been aggregated, thus, only the samples
taken at 1h and 2 h were considered for the calculation of the propagation efficiency.
Comparison of the amount of pelleted material (PrP in pellet vs. PrP in supernatant) by
total protein staining (Fig 5A) shows that around 50% of the total PrP in the unseeded sample
is in the pellet. This is composed entirely by non-infectious amorphous aggregates which are
highly PK-sensitive (Fig 5B and 5C), providing an estimation of the maximum percentage of
amorphous aggregates that could be formed in seeded reactions and which is subtracted from
the total pelleted material found in seeded PMSA reactions for the final calculation of conver-
sion efficiency. The seeded reaction reveals a faster aggregate formation, with all the PrP pel-
leted after 2 h of reaction. This pelleted material is purportedly composed by PK-sensitive
amorphous aggregates, PK-sensitive infectious prions and infectious protease-resistant prions
(Fig 5C).
Fig 2. Propagation capacity of L-seeded-PMCA and L-seeded-PMSA recombinant prions in PMCA and PMSA.
The propagation efficiency of both recombinant prions in vitro in PMCA in comparison with PMSA was evaluated by
serial dilutions of the seeds (from 10−1 to 10−7) in the same substrate (bank vole 109I rec-PrP complemented with
dextran sulfate) subjected to 24 h rounds of PMCA and PMSA. Protease resistant rec-PrP formation was monitored by
PK-digestion and western blot, using D18 mAb (1:5,000). L-seeded-PMSA showed a similar propagation capacity to
PMCA. This blot shows a slight difference (1 log) when comparing the propagation capacity of both seeds in PMCA
but not in PMSA. However, these small differences were not significant. Despite all the samples being run at the same
time, the blot was cropped as indicated by the vertical dotted line to avoid displaying unrelated samples. rec-PrP
(control): undigested bank vole rec-PrP protein.
https://doi.org/10.1371/journal.ppat.1008117.g002
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To calculate the percentage of PrP that misfolds into the latter two species, infectious but
just partially PK-resistant bona fide prions, the percentage of pelleted material was estimated
according to the PrP signal intensity in contrast to the amount of PrP in the supernatant and the
percentage of amorphous aggregates derived from PrP in the pellet of the unseeded reaction.
Therefore, considering that 100% of the PrP from the seeded reaction sediments after 2 h of
PMSA and that the maximum percentage of amorphous aggregates in the unseeded reaction cor-
responds to 50% of the total PrP, the conversion efficiency at 10−5 seed dilution was estimated to
be at least 50%. Although a greater amount of seed might reduce the formation of amorphous
aggregates by driving the misfolding towards bona fide recombinant prion conversion pathway,
Fig 3. Optimization of PMSA parameters to increase propagation efficiency. Variations of several operational
parameters for PMSA were tested using serial dilutions of the L-seeded-PMSA (from 10−1 to 10−8) in a substrate
composed of bank vole 109I rec-PrP complemented with dextran sulfate. For each parameter variation triplicates of
the dilutions were included and the maximum dilution that showed protease-resistant rec-PrP was monitored by PK
digestion and Western blot after one 24 h round of PMSA. Dilutions with detectable protease-resistant rec-PrP in each
triplicate are represented in different shades of blue. Studied parameters include: (A) Shaking speed, ranging from no
shaking (none) to 1,200 rpm; optimal propagation was achieved at 1,000 rpm; (B) Shaking/incubation intervals, from
continuous shaking to cycles of 60 s shaking and 60 min of incubation, the optimal result was with continuous shaking;
(C) Types of beads, several beads made of different materials or sizes were tested, some previously shown to improve
propagation in PMCA [84, 85]. Similar amounts of each bead type were added to the dilutions: zirconium silicate 1.0
mm and 0.5 mm, polytetrafluoroethylene (PTFE) 1.8 mm and steel 1.0 mm. Dilutions without beads were also
included. Propagation in the presence of zirconium silicate beads was significantly better, beads of PTFE or steel being
similar to the absence of beads. Although 0.5 mm zirconium beads were more consistent than the 1.0 mm ones both
reached 10−6 maximum dilutions and thus, 1.00 mm ones were chosen due to ease of handling; (D) Temperature
variations in the range tested from 37 to 42˚C, did not affect the propagation efficiency of seed greatly. However,
propagation from the lowest dilutions was achieved at 39 and 40˚C and so 39˚C was chosen as optimum temperature
setting; and (E) PrP concentration was evaluated in substrates varying from 0.125 μM to 2 μM. This is critical to
obtain optimal amounts of material for structural studies with in vitro recombinant prion propagation methods. A
balance is required between a high enough concentration to induce good propagation without wasting recombinant
PrP and minimizing the amount of non-misfolded PrP remaining at the end of the reaction which will need to be
eliminated prior to the structural studies. Below 1 μM PrP concentration was insufficient to efficiently propagate and
the substrate with the highest protein concentration was best, so 2 μM was chosen as preferred concentration.
https://doi.org/10.1371/journal.ppat.1008117.g003
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the high dilution used for the seeded reaction allows minimization of the effect of the seed in the
formation of amorphous aggregates versus bona fide prions. This 50% of amorphous aggregates
would be the worst case scenario, in which the effect of the seed on driving the misfolding path-
way towards bona fide prion propagation is negligible and the amorphous aggregates formed are
equal to the maximum amount observed in the unseeded reaction. Nonetheless, it is likely that
seeding may reduce amorphous aggregate formation and that this is an underestimation of the
real conversion efficiency, which was probably greater than the 50% calculated.
Relative amounts of PK-resistant and PK-sensitive bona fide prions were also estimated by
evaluating the self-propagation ability of the same PK-digested and undigested PMSA product
(Fig 6). This digested or undigested seeds were serially diluted in fresh substrate and submitted
to a 24 h PMSA.
The same amount of PK-treated seed showed approximately 10 to 100 folds lower propaga-
tion capacity than the undigested seed, suggesting that up to 90–95% of the seed could be com-
posed of PK-sensitive auto-propagative prions.
Biochemical characterization of the scaled-up seed
Prior to its biochemical characterization, the capacity for stable self-propagation of the recom-
binant dextran-complemented seed was evaluated. For that, 33 serial rounds of PMSA were
Fig 4. Propagation of serially diluted L-seeded-PMSA using different volumes and tube sizes. A) Western blot
showing propagation capacity of L-seeded-PMSA in PCR tubes (0.2 ml) and 2 ml and 5 ml tubes using dilutions 10−1 to
10−8 after a single 24 h round of PMSA. All samples were digested at 25 μg/ml of PK. The three tube sizes allow
propagation of the seed up to dilutions of 10−5–10−6 with slightly better results in 2 ml and 5 ml tubes, demonstrating the
system can be adapted to the production of large volumes. Brain (control): undigested TgVole whole brain homogenate.
mAb D18 (1:5,000). B) Total protein staining of the serial dilution performed in the 5 ml tubes. 500 μl of each dilution
were digested with PK (25 μg/ml) and concentrated by centrifugation after digestion. The resuspended pellets were
subjected to electrophoresis and total protein stained with BlueSafe. Intense signal could be detected even at a dilution of
10−6 confirming the suitability of the system for propagation of large volumes. rec-PrP (control): undigested bank vole
rec-PrP protein. rec-PrPSc (control): original seed digested and concentrated as per the other samples.
https://doi.org/10.1371/journal.ppat.1008117.g004
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Fig 5. Propagation efficiency in PMSA analyzed by sedimentation and protease digestion. A) Total protein
staining of the undigested pellet (P) vs. supernatant (St) fractions to monitor the amounts of aggregated and
soluble rec-PrP in the course of PMSA. Fractions corresponding to 1 and 2 h from a 24 h-round of unseeded and
seeded (1:100,000 dilution) PMSA reactions were collected at the indicated time points, in which all the PrP from the
supernatant of the seeded sample was converted to insoluble material. Samples were centrifuged at 19,000 g for 15 min
and supernatant and pellet (resuspended in a volume equal to that of the collected fraction) subjected to
electrophoresis and stained for total protein with BlueSafe. The amount of aggregated PrP (pellet) and soluble PrP
(supernatant) were compared in order to calculate conversion efficiency without protease digestion due to the
possibility of protease-sensitive prions being an important part of the PMSA product. The unseeded reaction indicated
the maximum amount of amorphous aggregates that can be formed after 2 h of the process was approximately 50% of
the total PrP, which was subtracted from the aggregated fraction of the seeded reaction to estimate bona fide
misfolding percentage. A highly diluted seed (10−5) was used to minimize its effect on driving the misfolding process
towards the bona fide prion formation pathway at the expense of the formation of amorphous aggregates. Therefore, it
is likely that bona fide prion propagation efficiency is higher than the 50% estimated based on the amount of
amorphous aggregates formed in an unseeded reaction. Mw: molecular weight marker. Control: total PrP on the
substrate at time 0, before PMSA. B) Total protein staining of protease digested PMSA products at 2 h. To
differentiate samples containing only amorphous aggregates (non-infectious completely protease-sensitive) from
samples containing bona fide recombinant prions (partially protease-resistant), samples form unseeded (Us) and
seeded (S) reactions were collected after 2 h of PMSA and digested with PK (25 μg/ml) for 1h at 42˚C. As expected, the
unseeded reaction contained only PK-sensitive aggregates, while the seeded one showed the characteristic PK-resistant
core that remains after amino-terminal digestion, indicating that at least part of the misfolded material formed in the
seeded reaction were PK-resistant bona fide prions. Mw: molecular weight marker. C) Potential infectivity of
unseeded and seeded samples by brain-PMCA. In order to confirm that the unseeded sample did not contain PK-
sensitive bona fide prions able to propagate their conformation in brain-derived PrP whereas the seeded sample was,
the two samples at 2 h were used as seeds to inoculate TgVole (1x) brain homogenate at 1:10 dilution and submitted to
brain-PMCA. The PMCA products were PK-digested and visualized by Western blotting, which showed the presence
of PK-resistant PrP for both seeded samples while there was no detectable propagation for the unseeded ones after 1
and 2 h PMSA. The high dilution of the original L-seeded-PMSA inoculum (10−5) protects against the possibility of
being the original inoculum and not the propagated material, the result of brain PrPC misfolding, since the
propagation capacity of L-seeded-PMSA in brain-PMCA did not reach 10−6 dilution. mAb: D18 (1:5,000). Mw:
molecular weight marker. Control: undigested Tgvole (1x) PrP.
https://doi.org/10.1371/journal.ppat.1008117.g005
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performed at 1:1,000 to a 10−100 dilution of the initial seed that was used for subsequent exten-
sive biochemical characterization studies including PK digestion, electrophoresis, total protein
staining and epitope mapping with several antibodies. All studies revealed no alteration of its
electrophoretic migration pattern after protease digestion (Fig 7).
Total protein staining and epitope mapping of the same sample showed major bands of;
~15 kDa, corresponding to complete protease-resistant rec-PrP with partial N-terminal diges-
tion encompassing residues ~97–231 according to the antibodies used, ~9 kDa formed by pro-
teolytic fragments containing residues ~153–231, and ~2 kDa that includes regions 97 to ~117
of the PrP [see (!) in Fig 7C]. Another two minor bands reflected other PK cleavage sites
yielding two fragments of ~12 and ~6 kDa [see green and red bands in Fig 7C]. To evaluate
the PK resistance, equal amounts of the misfolded recombinant PrP were digested with
increasing concentrations of proteinase-K (from 50 to 1,000 μg/ml; rec-PrP:PK ratio from 1:2
to 1:40) at 42˚C for 1 h followed by visualization by electrophoresis and total protein staining
(Fig 7B). At 1,000 μg/ml of PK digestion was incomplete indicating high resistance to protease
characteristic of many prion isolates.
Analysis of PK-treated PMSA product by ESI-TOF allowed the exact identification of several
PK-resistant fragments (Supplementary information, S1 Table) and confirmed that PK cleaves
between positions H96/N97 and N97/Q98 generating amino-terminal ragged ends, and also vigor-
ously between positions E152/N153 and N153/M154 generating PK-resistant N- and C-terminal
shorter fragments of ~5–6 and ~9 kDa, respectively. Very minor peaks corresponding to addi-
tional minor cleavages at A116/A117, S132/A133 and M134/S135 were also detected. These data are
consistent with results obtained from SDS-PAGE/total protein staining and epitope mapping
analyses (Fig 7C). The higher sensitivity of WB and the large amount of loaded sample allowed
identification of some additional PK cleavage sites within the misfolded PrP propagated by
PMSA that were not observed previously in the WB done with the usual sample amounts.
In order to gain some insight on the ultrastructural characteristics of the L-seeded-PMSA
sample, the size distribution of the aggregates was evaluated by zonal sedimentation analysis
Fig 6. Self-propagation ability of protease-digested and undigested L-seeded-PMSA. To estimate the amount of
PK-sensitive bona fide recombinant prion fraction in the L-seeded-PMSA sample, the propagation capacity of PK-
digested and undigested seeds was compared by serial dilution (from 10−4 to 10−8) on PMSA and monitored by PK
digestion and Western blot. The PK-digested L-seeded-PMSA seed showed reduced propagation capacity of
approximately 1–2 logs compared to the non-digested seed, indicating that approximately 90–95% of the seed could be
composed of PK-sensitive prions. mAb D18 (1:5,000). Mw: molecular weight marker. Control: undigested bank vole
rec-PrP.
https://doi.org/10.1371/journal.ppat.1008117.g006
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on continuous sucrose density gradient. The sample produced in PMSA, either undigested or
digested with PK, was submitted to ultracentrifugation through 10–80% sucrose gradient to
determine the degree of quaternary structure heterogeneity by total PrP or PrPres detection in
Western blot (Supplementary information, S3 Fig). A continuous distribution of PrP aggre-
gates is observed starting in fractions with around 30–35% sucrose to the end of the gradient
with 80% sucrose with no monomeric PrP in upper fractions. This suggest that all PrP is mis-
folded during the process forming mostly large fibrillary aggregates with quite heterogeneous
sizes, densities ranging from 1.1 g/cm3 to higher than 1.3 g/cm3 [44]. The analysis of PK-
treated sample reveals a similar sedimentation velocity pattern, with a continuous distribution
of aggregates from 40–45% sucrose to 80%, indicating that part of the smallest aggregates
could be PK-sensitive or composed by amorphous aggregates. In any case, the linearity of the
signal and the major signal intensity towards the bottom fractions clearly indicates that the
sample is mainly composed by very big PK-resistant aggregates able to reach and even cross
the 80% sucrose gradient, although smaller PK-resistant aggregates are also detected as proof
of some quaternary structure heterogeneity dominated by large aggregates.
Biological characterization of the scaled-up seed
Infectivity and transmissibility in animal models. The definitive demonstration of the
infectivity of the recombinant seed propagated by PMSA, in comparison with the original
inoculum generated by PMCA, was done by intracerebral inoculation in TgVole (1x) mouse
and bank vole models, both bearing bank vole I109 PrP with similar expression levels (Supple-
mentary information, S2 Fig).
In TgVole (1x) model, which is very similar to bank voles as shown by similar short incuba-
tion periods for CWD-vole prion strain [58±1 days post inoculation (dpi) in TgVole and 35–
40 dpi in bank voles] in both models [18], the original PMCA-derived seeds caused clinical
disease in all inoculated animals with incubation periods of 175±6 (Prnp0/0 complemented)
and 326±9 dpi (dextran sulfate complemented). Two different preparations of the PMSA-
adapted seed showed the same attack rate (100%) with incubation times of 250±4 and 266±3
dpi. Negative control groups inoculated with non-misfolded rec-PrP and with the same rec-
PrP fibrillated following another protocol [45] showed no signs of disease after > 500 dpi, as
expected (Table 1).
A second passage was performed using TgVole (1x) animals, which showed shorter incuba-
tion periods of 120±1 dpi for the PMCA-derived seed and of 116±2 dpi for the PMSA-derived
one. A biochemical analysis of Proteinase-K (PK)-resistant PrPSc in brain homogenates from
these inoculated TgVole (1x) showed that the CWD-vole and all the bona fide misfolded rec-
PrPs accumulated in the classical PrPSc three-banded electrophoretic migration pattern. How-
ever, brains from animals inoculated with the non-infectious fibrillary rec-PrP and non-fibril-
lated rec-PrP were devoid of any PK-resistant bands (Fig 8).
Fig 7. Biochemical characterization of L-seeded-PMSA. A) The ability of L-seeded-PMSA to self-propagate indefinitely shown through 30 serial rounds
of PMSA at 1:1,000 dilution. 500 μl of the original seed (100 dilution), the product of round 17 of PMSA (10−50 dilution) and the product of round 33
(10−100 dilution) were PK-digested, concentrated by centrifugation and visualized by total protein staining and showed no detectable pattern differences
throughout the propagation process. B) Protease-K (PK) resistance of L-seeded PMSA was evaluated by submitting fractions of the same sample to
increasing PK concentrations for 1h at 42˚C. L-seeded-PMSA showed high resistance to protease, as the main PK-resistant bands are maintained even at
the highest PK concentration used. C) Identification of the proteolytic fragments of L-seeded-PMSA by epitope mapping was performed with the same
PK-digested and concentrated sample divided in seven that were stained for total protein to guarantee equal protein amounts in each lane. The stained gel
was then transferred for Western blotting and the following antibodies were used for epitope mapping: 12B2 (1:2,500), 9A2 (1:4,000), 7D9 (1:1,000), D18
(1:5,000), Saf83 (1:400), Sa84 (1:400) and POM19 (1:10,000). The theoretical reconstruction of the PrP fragments recognized by each antibody are
represented in the cartoon, the most abundant fragments were (see arrows) ~15 (pink), ~9 (purple) and ~2 (orange) kDa. Another two minor bands reflect
other PK cleavages yielding two fragments of ~12 and ~6 kDa (green and red bands, respectively). These fragments are not always detected by all the
antibodies used for the epitope mapping due to their low amounts, below the detection limit of some of the antibodies. MW: Molecular weight.
https://doi.org/10.1371/journal.ppat.1008117.g007
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Regarding bank vole I109, the same PMCA and PMSA-derived seeds caused disease in 239
±46 dpi [10] and 318±3 dpi, respectively, again with 100% attack rates (Table 2).
The biochemical and immunohistopathological examination of the brain samples from
inoculated bank voles shows classical PK-resistant PrP and clear PrPSc plaque deposition (Fig
9), confirming the bona fide prion disease induced by L-seeded-PMSA inoculum.
Both seeds were able to cause disease in all the inoculated animals, either bank voles or
transgenic mouse models with no PrP overexpression, with similar incubation times and com-
plete attack rate. Therefore, the PMSA propagates this recombinant infectious prion faithfully,
providing material suitable for structural studies.
Table 1. First passage of PMCA and PMSA-adapted recombinant samples inoculated into TgVole (1x) mice.
Inoculum Substrate Model Survival time of positive animals
(dpi) (mean±SEM)
Attack ratea
CWD-vole Brain TgVole 58±1 10/10 (100%)
H/L-seeded-03 Brain TgVole 175±6 8/8 (100%)
L-seeded-PMCA PMCA TgVole 326±9 5/5 (100%)
L-seeded-PMSA (1)b PMSA TgVole 266±3 9/9 (100%)
L-seeded-PMSA (2)b PMSA TgVole 250±4 10/10 (100%)
Fibrillary vole rec-PrP Urea TgVole >500 0/6 (0%)
Non-fibrillary vole rec-PrP - TgVole >500 0/6 (0%)
a Data obtained based on clinical signs and protease-resistant PrP detection.
b (1) and (2) indicate two different preparations of L-seeded-PMSA done independently by PMSA propagation of L-seeded-PMCA in a substrate based on recombinant
bank vole I109 PrP.
SEM: Standard Error of Mean. dpi: day post inoculation.
https://doi.org/10.1371/journal.ppat.1008117.t001
Fig 8. PrPSc detection in diseased TgVole (1x) brains inoculated with CWD-vole, H/L-seeded-03, L-seeded-
PMCA, L-seeded-PMSA, non-infectious fibrillary rec-PrP and non-fibrillated rec-PrP. Biochemical analysis of
Proteinase-K (PK)-resistant PrPSc in brain homogenates from TgVole (1x) inoculated with different misfolded PrPs:
CWD-vole, H/L-seeded-03, L-seeded-PMCA, L-seeded-PMSA (I & II), non-infectious fibrillary rec-PrP and non-
fibrillated rec-PrP. Representative TgVole brain homogenates were digested with 200 μg/ml of PK. The CWD-vole and
the PMCA and PMSA-derived misfolded rec-PrPs inoculated TgVole brains accumulated a classical PrPSc type
characterized by a three bands electrophoretic migration pattern. Brains from animals inoculated with the non-
infectious fibrillary rec-PrP and non-fibrillated rec-PrP, used as negative controls, did not show any PK resistant band.
D18 monoclonal antibody (1:5,000). Control: undigested TgVole (1x) whole brain homogenate. MW: Molecular
weight. dpi: days post-inoculation at which each animal was culled due to neurological clinical signs.
https://doi.org/10.1371/journal.ppat.1008117.g008
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Table 2. First passage of PMCA and PMSA-adapted recombinant samples inoculated into bank voles.
Inoculum Substrate Model Survival time of positive animals
(dpi) (mean±SEM)
Attack ratea
CWDb Brain Bank vole 37±1 9/9 (100%)
L-seeded-PMCAc PMCA Bank vole 239±46 8/8 (100%)
L-seeded-PMSA (1) PMSA Bank vole 318±3 4/4d (100%)
a Data obtained based on clinical signs and protease-resistant PrP detection.
b Data obtained and published previously using CWD: Chronic Wasting Disease adapted to bank vole I109 (10).
c Data obtained and published previously using the dextran-complemented recombinant sample (10).
d From a group of eight animals, four had to be killed due to unrelated intercurrent disease and were excluded from these calculations.
SEM: Standard Error of Mean. dpi: day post inoculation.
https://doi.org/10.1371/journal.ppat.1008117.t002
Fig 9. PrPSc detection and histopathological analysis of diseased bank vole 109I brains inoculated with CWD-vole,
L-seeded-PMCA and L-seeded-PMSA. A) Biochemical analysis of Proteinase-K (PK)-resistant PrPSc in brain
homogenates from bank vole I109 inoculated with the misfolded rec-PrPs: L-seeded-PMCA and L-seeded-PMSA, and
CWD-vole as control. Representative bank vole brain homogenates were digested with PK (200 μg/ml). All rec-PrPSc
inoculated bank vole brains accumulated a classical PrPSc type characterized by a three-banded electrophoretic
migration pattern, indistinguishable from the CWD-vole inoculated vole brains. 9A2 monoclonal antibody (1:5,000).
Control: undigested bank vole whole brain homogenate. MW: Molecular weight. B) Brain deposition of PrPSc in the
mediodorsal thalamic nucleus and the hippocampus of bank voles inoculated with L-seeded-PMCA or L-seeded-
PMSA was assessed by immunohistochemistry using the monoclonal antibody 6C2 (1:300). Note, with both seeds,
deposition of PrPSc could be observed in the mediodorsal thalamic nucleus but not in the hippocampus.
https://doi.org/10.1371/journal.ppat.1008117.g009
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Specific infectivity of L-seeded-PMSA. The end-point in vivo titration and determina-
tion of specific infectivity was assessed in TgVole using tenfold dilutions of L-seeded-PMSA
being 10−4 (Table 3).
From these data, the specific infectivity of L-seeded-PMSA in TgVole (1x) was also calcu-
lated using the Spearman-Karber method [46]. Taking into account that the dose causing fatal
disease in 50% of the animals (LD50) is between dilutions 10
−4 and 10−5, of which 10 μl were
inoculated with a total PrP content of 0.25 μg, specific infectivity was calculated to be of 6.34 x
104 / μg of PrP in TgVole (1x).
Preliminary ssNMR study of the recombinant prion
With this highly scalable method that is able to propagate a bona fide recombinant prion, pre-
paring up to 400 ml of misfolded seed per day is easily feasible in any laboratory requiring
large amounts of material for structural studies. As proof of concept, a preliminary ssNMR
experiment was conducted using 400 ml of a PMSA product containing dual isotopically
labeled bank vole I109 rec-PrP (C13 and N15), seeded with unlabeled L-seeded-PMSA 1:100
and prepared as follows. To obtain a misfolded sample to act as a seed, with at least 99.99% of
the protein labeled, two serial rounds of PMSA were performed using in the first passage, the
non-labeled L-seeded-PMSA seed diluted 1:100. Subsequently, 4 ml of the isotopically labeled
seed was scaled 100-fold up to reach, in a single round (24 h), 400 ml of misfolded material
labeled at 99.9999%. With an estimated efficiency of conversion of at least 50%, approximately
9 mg of converted material were obtained from the 400 ml at 2 μM rec-PrP concentration
(containing around 18.4 mg of rec-PrP). However, the final amount of PK-digested material
was approximately 0.75–1.0 mg, indicating that around 90–95% of the misfolded material was
PK-sensitive, in agreement with the ability of the PK-undigested L-seeded-PMSA seed to prop-
agate by PMSA 10–100 times (1–2 logs) more than when is PK-digested. In order to reduce
the 400 ml of seed produced by PMSA to the standard ssNMR working volumes of 10–100 μl,
the sample was digested with PK (25 μg/ml for 1 h at 42˚C), based on the previous characteri-
zation. After digestion, the sample was concentrated by centrifugation.
An INEPT spectrum recorded at 15˚C nominal temperature did not show any signals, dem-
onstrating that misfolded rec-PrPSc does not contain any highly flexible parts [47]. Conversely,
13C CP/MAS based NMR spectra which exhibit signals from immobilized parts of the protein,
showed the full set of resonances. Additionally, two-dimensional NMR-spectroscopy was pos-
sible (Fig 10) in which signal sets for the spin systems of the amino acid types alanine, threo-
nine, isoleucine and valine were clearly identified.
The preliminary results obtained from the ssNMR spectra demonstrate that large amounts
of isotopically labeled prions suitable for this and other biophysical methods can be propagated
by PMSA, to enable elucidation of the three-dimensional structure of prions or at least of the
most relevant structural motifs.
Table 3. Titration of the PMSA-adapted recombinant samples inoculated into TgVole (1x).
Inoculum Dilution Model Survival time of positive animals
(dpi) (mean±SEM)
Attack ratea
L-seeded-PMSA (1) 10−1 TgVole 266±3 10/10 (100%)
L-seeded-PMSA (1) 10−2 TgVole 281±6 4/4 (100%)
L-seeded-PMSA (1) 10−4 TgVole 321±6 5/5 (100%)
L-seeded-PMSA (1) 10−5 TgVole 434±21 2/5 (40%)
a Data obtained based on neurological clinical signs and protease-resistant PrP detection.
SEM: Standard Error of Mean. dpi: day post inoculation.
https://doi.org/10.1371/journal.ppat.1008117.t003
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Discussion
Deciphering the three dimensional structure of prions at high resolution has been long hin-
dered by several characteristics of these proteins. Isolation and purification of PrPSc from
brain homogenates in sufficient quantities required for most of the high-resolution biophysical
techniques is extremely difficult, despite advances in GPI-deficient PrP-expressing animal
models [34]. Although in vitro prion conversion assays and the use of recombinant PrP
addressed many of the purification issues [1–10], that PrPC and, in particular, rec-PrP can mis-
fold into multiple different conformations and aggregated states (amorphous, amyloid fibrils
or 2D crystals) with some unrelated to disease or some disease-associated but not transmissi-
ble, complicates structural studies [48]. Even among transmissible, diseases-associated aggre-
gates, known as PrPSc, the co-existence of distinct strains and the variety of quaternary
structures ranging from oligomers to fibrils with different sizes make structural characteriza-
tion of prions extremely challenging [37]. Considering the variety of misfolded forms PrP can
adopt and the lack of knowledge on the event itself, it is not unexpected that the propagation
of recombinant prions in vitro resulted in many different products ranging from biologically
inert aggregates to highly transmissible and neurotoxic species or bona fide prions [1–10, 12,
15, 21]. We and others have previously reported the generation of recombinant prions using
PMCA and Prnp0/0 brain homogenates or specific cofactors [5, 8–10, 14, 15, 49]. Our group
also proposed a way to reduce the heterogeneity of these in vitro generated prions by propaga-
tion in the presence of specific cofactors [10]. However, lack of knowledge of the molecular
events underlying prion propagation by PMCA and the difficulty controlling sonication
parameters render highly variable results; i. e. non-infectious misfolded rec-PrP was produced
with the exact conditions that had previously yielded a highly infectious recombinant prion
[12, 50]. Additionally, the complexity of the equipment necessary for PMCA inherently limits
scalability and generation of large amounts of misfolded material. Herein we present a new
system that overcomes all the issues of complexity, variability and scalability of PMCA, which
allows generation of suitable material for high-resolution protein structural studies.
Fig 10. ssNMR. Right side: 2D 13C/13C correlation spectrum employing proton driven spin diffusion (50 ms) for
homonuclear polarization transfer. Cross correlation signals of selected amino acids are highlighted in the spectrum.
On the left side, four representative 1D slices through the spectrum are displayed. The spectrum was recorded at a
nominal temperature of 0˚C and a field strength of 14.1 T with a spinning frequency of 11 kHz.
https://doi.org/10.1371/journal.ppat.1008117.g010
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Fundamentally based on the PMCA: with the same substrate preparations complemented
with a single cofactor (dextran sulfate) for recombinant prion propagation [10], zirconia/silica
beads shown previously to enhance the performance of classical brain-homogenate based
PMCA [51] and reaction temperature, the critical difference is the substitution of sonication
by shaking, hence the name Protein Misfolding Shaking Amplification (PMSA). Although
shaking has been used extensively in several cell-free systems for amyloid formation or prion
propagation, none showed the capacity to yield recombinant prions capable of causing classi-
cal clinical prion disorder with a 100% attack rate, neurological signs, spongiform change and
misfolded PrP accumulation in the CNS upon first passage in wild-type animal models and
transgenic models devoid of PRNP gene overexpression [1, 5, 52]. Contrary to other methodol-
ogies and previous assumptions, PMSA shows that, under appropriately optimized conditions,
vigorous shaking provides sufficient energy to achieve bona fide prion propagation in the pres-
ence of an adequate concentration of the polyanionic cofactor dextran sulfate. Thus, the idea
that high energy input, as purportedly provided by sonication in PMCA, could be required to
cause fibril breakage and efficiently misfold PrP into its infectious counterpart in vitro needs
to be reexamined [53].
The adaptation of an infectious recombinant prion generated by PMCA to this new PMSA
system was successful and seemed to conserve biochemical features, as indicated by their elec-
trophoretic migration patterns after PK digestion and the ability to propagate on brain-based
substrates in a single round of brain-PMCA. In particular, the PK fragmentation pattern of L-
seeded-PMSA was consistent with those reported for its precursor obtained by PMCA [33].
MALDI analysis of such samples produced spectra that were dominated by a large peak corre-
sponding to fragment N153-S231 and a group of peaks that were believed to correspond to dou-
bly N- and C-terminal-truncated fragments which the lower mass accuracy of MALDI did not
allow to identify, some of which would correspond to N97/Q98-E152/N153. Very small peaks,
corresponding to additional minor cleavages at A116/A117, S132/A133 and M134/S135, were
detected also. Conversely, some minor differences might exist between the two products. This
pattern of fragmentation, as discussed in our previous publication [33] strongly suggests that
both PMCA- and PMSA-generated recombinant PrPSc share the same architecture. Besides
the main cleavage at N97/Q98, which marks the division between the disordered N-terminal
tail and the compact ‘PrP27-30’ domain, a significant secondary cleavage site was seen for both
brain-derived and recombinant PrPSc at N153-M154 [32]. In recombinant prion samples, cleav-
age at this site was much more extensive than in brain-derived PrPSc, and the resultant N- and
C-terminal-truncated fragments were detected readily. We have proposed previously that the
secondary cleavage site, which is close to proline P158 might correspond to a particularly acces-
sible flexible linker connecting β-strands [54]. Other shared minor cleavage sites also support
the notion that brain-derived PrPSc and the recombinant prion described here are comprised
of a set of β-strands connected by flexible linkers, spanning from position 90–98 to the C-ter-
minus, and that the identity of the β-strands and linkers are similar in both molecules. The
data from epitope mapping and ESI-TOF of the proteolytic fragments of this recombinant
prion could fit with one of the suggested structural models for prions, the 4-rung β-solenoid
model [34, 48], according to the scheme proposed (Fig 11). However, it does not unequivocally
exclude the possibility of other structures giving rise to the same proteolytic fragments.
Another possibility that we cannot completely exclude, although it contradicts Occam´s
principle, is that a mixture of strains is responsible for the multiple-banded pattern, some pro-
teolytic fragments originating from certain conformer, while other fragments would derive
from different structural variants. Our attempts to separate this possible strain mixture
through clonal selection of limiting dilutions (highest dilution able to propagate in each PMSA
round was diluted from 10−1 to 10−8 in a subsequent round and this process was repeated
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along more than 5 serial rounds) always resulted in the same proteolytic fragments, suggesting
a single conformer or the existence of multiple conformers with exactly the same propagation
abilities and thus, undistinguishable by this method.
The sedimentation velocity analysis could also shed some light on the heterogeneity of the
sample produced by PMSA, mainly in terms of quaternary structure heterogeneity. This meth-
odology has been applied previously to establish the relation between infectivity and specific
prion aggregates [55], to determine the heterogeneity of PrP assemblies in prions from brains
[56] and to characterize prion strains based on the differential properties of the assemblies
present in each isolate [57]. The ultrastructural heterogeneity on samples containing PrP
assemblies, either recombinant or brain-derived, can indicate the presence of a continuous
range of aggregates with the same tertiary structure but different fibril sizes or the existence of
structurally distinct conformers that adopt slightly different quaternary structures. The contin-
uous distribution for aggregates observed with L-seeded-PMSA, with predominance of very
large aggregates and similar pattern of PK-digested and undigested samples (Supplementary
information, S3 Fig), together with the other biochemical characteristics evaluated, suggests a
single population with a unique tertiary structure forming assemblies of distinct sizes. None-
theless, the existence of slightly different tertiary structures giving rise to distinct assemblies
cannot be completely discarded with the present evidences. The first scenario should not pose
a great limitation for the ssNMR studies aimed to elucidate the tertiary structure of our recom-
binant PrPres preparations, since the main problems associated to sample heterogeneity are
not related to the size of the assemblies (i. e. number of monomers within a fibril). As long as
the tertiary structure is homogeneous the large majority of monomers within the fibrils will
have the same surrounding (same distances between residues) and the few molecules at the
fibril ends will be too few to be detected. So the average fibril length is not necessarily
Fig 11. Graphical representation of the PrP fragments identified after PK-digestion of L-seeded-PMSA by epitope
mapping and ESI-TOF and their origin based on the 4 rung β-solenoid model for PrPSc. The identification of the
main proteolytic fragments of L-seeded-PMSA after PK digestion (characteristic whole PK-resistant core after amino
terminal digestion represented in blue, encompassing residues 89–231) by epitope mapping and ESI-TOF showed four
major cleavage sites at positions ~97, ~117, ~133 and ~153 that give rise to five fragments of ~15 (pink, encompassing
residues ~97–231, rungs 1 to 4), ~11 (green, encompassing residues ~133–231, rungs 2/3 to 4), ~9 (purple,
encompassing residues ~153–231, rungs 3 and 4), ~6 (red, encompassing residues ~97–153, rungs 1 to 3) and ~2
(orange, encompassing residues ~97–117 rungs 1 and 2) kDa. Based on the assumption that PK cleaves accessible and
flexible sites of the protein, most likely loops linking β-strands, the main fragments and cleavage sites may indicate that
the overall structure of L-seeded-PMSA could fit with the 4-rung β-solenoid model proposed previously for brain-
derived prions [34].
https://doi.org/10.1371/journal.ppat.1008117.g011
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correlated with the monomer structure and thus, variations in particle size per se (considering
the same structure for monomers forming them) would not affect the quality of the NMR spec-
tra. The proof of the relative importance of fibril-length heterogeneity is provided by other
amyloid structures solved using preparations with variable length fibrils and oligomers [58]. In
the less probable second scenario, the different monomeric structures within the sample
would be critical for structural resolution by ssNMR but this would also lead to structural poly-
morphism (i.e. different fibril morphologies like straight/twisted and it may also be accompa-
nied by different numbers of monomers per layer). Presumably, such morphological
differences would be reflected on different majoritarian populations with distinct density in
the sedimentation velocity profile. The issue could also be addressed by negative stain EM [59]
but only if differences were quite notorious. Moreover, despite fibril polymorphism can be
associated with different monomer folds, fibrils with very different fiber morphology but still
the identical monomer conformations have also been demonstrated [60]. In any case, any
effect of the morphological variability of the PrP fibrils will be continuously monitored during
the ssNMR spectra generation, in order to introduce further improvements in sample prepara-
tions, if required, to solve issues related to quaternary structure of assemblies.
Regarding the biological properties of L-seeded-PMSA upon inoculation in TgVole (Table 1)
and bank voles (Table 2), there is no doubt about its infectivity and the capacity to cause a bona
fide prion disease. It is noteworthy that differences in incubation times were detected between
TgVole and bank voles in the first passage of L-seeded-PMSA, despite the identical PrP sequence
and very similar expression levels (S2 Fig). Although unexpected, this difference might be
explained by the differences between both models and the existence of a transmission barrier
between the recombinant inoculum and the PrPC from brain. The significant reduction of disease
incubation times in a second passage observed in TgVole for L-seeded-PMSA (from 266–250 dpi
to 116 dpi) and also for L-seeded-PMCA (from 326 dpi to 120 dpi) strongly suggest the existence
of a transmission barrier, most likely due to the absence of glycosylation and GPI anchoring of
the recombinant inoculum. Usually, a transmission barrier is associated to prolonged incubation
times upon first passage and higher dispersion in disease onset and duration between animals of
the same group [61], but may also enhance the effect of small differences in PrP expression levels
and the genetic background of the models used to evaluate infectivity. This could be the reason
for the differences observed in incubation times, since small differences in expression levels unde-
tectable by western blotting are plausible and genetic background differences obvious being two
different species. In any case, L-seeded-PMSA with 100% attack rates in both models, is undoubt-
edly infectious and gives rise to a classical prion disorder with all its hallmarks.
Despite the possibility of strain mixtures could not be definitively excluded, the stable serial
propagation of this prion over 33 rounds of PMSA at a dilution of 1:1,000 demonstrated its sta-
bility and therefore suitability for high resolution structural studies, demonstrated further by a
good ssNMR spectra being obtained. Although the signal dispersion was limited in the prelim-
inary spectra shown in this manuscript (Fig 10), such that site-specific resonance assignment
was not feasible, it can clearly be seen that most of the cross-correlation signals have chemical
shifts which are indicative of β-strand-like conformations, in agreement with the β-sheet rich
secondary structure of amyloid fibrils. However, single residues may have random-coil or even
α-helical conformation. Further structural characterization, such as the determination of the
registry and supramolecular arrangement of the β-strands within the fibril will be possible
despite a lack of a site-specific resonance assignment and in the presence of some degree of
structural heterogeneity if dedicated labeling schemes and pulse sequences for distance mea-
surements are applied [62–64].
The titer of recombinant prions produced in vitro has always been a concern regarding the
biological significance of the samples analyzed and their resemblance with brain-derived
A largely scalable new method to produce infectious recombinant prions
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008117 October 23, 2019 20 / 33
prions. The possibility of obtaining large amounts of non-infectious self-propagative aggre-
gates that could resist PK treatment together with bona fide prions or the existence of heteroge-
neous strain mixtures are complicated issues to assess. The specific infectivity of our
intracerebrally inoculated L-seeded-PMSA preparation according to the Spearman-Karber
method is 6.34 x 104 LD50 / μg of PrP in TgVole (1x). This is similar, in fact slightly higher,
than that obtained for the first highly infectious synthetic prion generated with RNA and
POPG as cofactors in wild type mice (104 LD50 / μg of PrP) [65]. More recently, the same
authors reported on a recombinant mouse PrPSc also made with RNA and POPG as cofactors,
with higher specific infectivity, namely, 2 x 105 LD50 / μg of PrP; however this was assessed in a
transgenic mouse model (Tga20) that overexpresses mouse PrP at 8x the level of a wild type
mouse and has repeatedly shown to exhibit increased susceptibility to prion infection com-
pared to wild type animals [66], therefore, comparison is not straightforward. Other phospho-
lipid-complemented preparations have been reported with specific infectivity of 2.2 x 106 LD50
/ ug of PrP [15], in this case tested in wild type models, and 5.6 x 105 LD50 / μg of PrP using the
same substrate preparation but a different in vitro propagation method [67]. All in all, the spe-
cific infectivity of our preparation lies within the range of values reported. It should be noted
that while differences in infectivity titer of different samples of a given PrPSc strain are a direct
indication of purity and structural integrity, comparing specific infectivity of different PrPSc
strains is problematic, as different strains exhibit not just different incubation times but also
different specific infectivity, a classic example being the different properties of Drowsy and
Hyper [68]. Furthermore, the propagation dynamics can be decisively altered by the quater-
nary structure that each strain or even specific preparation of a given strain acquires in vitro in
comparison with the behavior of PrPSc formed or transmitted in the encephalon [69]. It should
be noted also, that specific activity is usually lower in recombinant prions due to lack of post-
translational modifications [49, 70]. All of the above likely explains the range of specific infec-
tivity reported for different strains of infectious recombinant PrPSc which, on the other hand,
differ clearly from the several reported propagative but non-infectious PrP samples, whose spe-
cific infectivity is essentially zero [12, 21]. In this respect, it is noteworthy that in contrast to
other methods reported [12, 21, 45, 49], we have never observed generation of similar non-
infectious propagative PrP species with our method. In fact, we have purposefully tried by
introducing an array of different minor changes in the experimental conditions, with the
objective of obtaining such material for comparative purposes, and have never been able to
propagate such non-infectious conformers. This, together with the sedimentation velocity
analysis and our cloning studies (vide supra) makes very unlikely the possibility that our mate-
rial consists of a mixture of a small quantity of a highly infectious material and a bulk of
“inert”, non–infectious material, a very important consideration for structural studies.
Overall, we demonstrate here that shaking can be used to continuously propagate infectious
recombinant prions as long as appropriate conditions and specific cofactors, such as dextran
sulfate, are used. Moreover, we present a set of tools to extensively characterize misfolded PrP
species generated in vitro, including a method to evaluate potential infectivity in vitro (brain-
PMCA) prior to the more costly and protracted bioassays. The simplicity, scalability and
robustness of this novel propagation method makes it easily implementable in any laboratory
interested on generating large amounts of recombinant prion samples which is likely to be suc-
cessful for other recombinant prions previously reported to propagate in vitro in presence of
single cofactors [8, 10, 14, 15, 21]. This system might be adapted to the propagation of other
prion strains apart from the one presented here and may open the way to detailed structural
studies on many different prions shedding light on the strain phenomenon. Importantly,
PMSA can become an invaluable source of distinct recombinant prions that can be labeled in
multiple ways and provide the amounts (in the milligram range) of infectious prions required
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for one of the most critical open questions underlying prion biology, the atomic structure of
this extraordinary pathogen.
Materials and methods
Preparation of purified recombinant PrP
Bacterial expression and purification of bank vole I109 recombinant PrP (amino acids 23–231)
(rec-PrP) was performed as described previously [71]. Briefly, pOPIN E expression vector con-
taining the wild type I109 bank vole Prnp gene was prepared by standard molecular biology
techniques using the oligonucleotides 5’ AGGAGATATACCATGAAGAAGCGGCCAAAG
CCTGG3’ and 5’ GTGATGGTGATGTTTGGAACTTCTCCCTTCGTAGTA3’ to derive the
PrP of interest from genomic DNA of bank vole I109 and clone in the pOPIN E expression
vector. E. coli Rosetta (DE3) Competent Cells (EMD Millipore) were transformed with the
expression vector using standard molecular biology procedures allowing the expression of the
recombinant protein in LB broth (Pronadisa) upon Isopropyl β-D-1-thiogalactopyranoside
(IPTG) (Gold biotechnology) induction. Although the protein does not contain a His-tag,
purification of the protein was performed with a histidine affinity column (HisTrap FF crude 5
ml, GE Healthcare Amersham) taking advantage of the natural His present in the octapeptide
repeat region of PrP. After elution in buffer (20 mM Tris-HCl, 500 mM NaCl, 500 mM imidaz-
ole and 2 M guanidine-HCl, pH 8), the quality and purity of protein batches was assessed by
BlueSafe (NZYtech) staining after electrophoresis in SDS-PAGE gels (BioRad). Finally, guani-
dine-HCl was added, to a final concentration of 6 M, for long-term storage of purified protein
preparations at -80˚C. For uniformly 13C, 15N labeled recombinant bank vole I109 PrP prepa-
ration, the same vector and E. coli strain were used growth in minimal medium composed of
M9 minimal medium (Thermofisher Scientific), 13C-glucose (3 g/liter) (Eurisotop, Cambridge
Isotope Laboratories) and 15NH4Cl (1 g/liter) (Cortecnet, Paris) as the sole carbon and nitro-
gen sources and 1M MgSO4 (1 ml/liter), 0.1 M CaCl2 (1 ml/liter), 10 mg/ml thiamine (1 ml/
liter) and 10mg/ml biotin (1 ml/liter). (Sigma-Aldrich). Induction of protein expression with
IPTG and purification using histidine affinity column was performed in the same way as for
the unlabeled recombinant PrP.
Generation of transgenic mice expressing bank vole PrP I109
The bank vole PrP (BvPrP) encoding isoleucine at residue 109 was synthesized according to
the BvPrP sequences (GeneBank accession numbers: AF367624.1 and EF455012.1) by mutat-
ing the residue 109 codon ATG to ATT. Transgenic vector, MoPrP.Xho was modified by
replacing the XhoI with BsiWI and FseI. The coding sequence of BvPrP I109 was cloned into
BsiWI and FseI sites of the modified transgenic vector and the coding sequence was confirmed
by DNA sequencing. The transgene expression cassette was then released with NotI and
microinjected into pronuclei of fertilized FVB/N oocytes. One transgenic line, referred to as
Tg(BvPrP-I109)C594+/–, was established. The expression level of BvPrPC in the brains of Tg
mice was determined by Western blotting assay using serial dilutions of brain homogenates
and was compared to that of wild type FVB mice. Tg(BvPrP-I109)C594+/- mice express the
same level of PrPC as the wild type FVB mice.
In vitro propagation of prions by PMCA and PMSA
Preparation of recombinant PrP-based in vitro propagation substrates was performed as
described previously for recombinant PrP-based substrates, either complemented with brain
homogenates from Prnp0/0 transgenic mice [9, 10, 71, 72] or with dextran sulfate sodium salt,
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from Leuconostoc spp. with molecular weights ranging from 6,500 to 10,000 (Sigma-Aldrich)
[10]. Briefly, the purified rec-PrP stored with 6 M of guanidine-HCl was diluted 1:5 in phos-
phate buffered saline (PBS) and dialyzed against PBS at 1:2,000 ratio for 1 h at room tempera-
ture. The dialyzed sample was centrifuged at 19,000 g for 15 min at 4˚C and the supernatant
used for substrate preparation. Rec-PrP concentration in the supernatant was measured (BCA
protein assay kit, Thermo Scientific) and adjusted to the working concentration, which, unless
otherwise indicated, was of 20 μM to reach a final concentration of 2 μM when diluted in the
substrate. The protein, after dialysis and concentration adjustment was mixed with conversion
buffer (CB) [71] 1:9 and dextran sulfate sodium salt, from Leuconostoc spp. with molecular
weights ranging from 6,500 to 10,000 (Sigma-Aldrich), was added to a final concentration of
0.5% (w/v). The substrate was aliquoted and stored at -80˚C until required.
Preparation of brain PrP-based in vitro propagation substrates. Brain PrP-based sub-
strates from transgenic mice expressing 4-fold or 1-fold of bank vole I109 PrP [TgVole (4x)
and TgVole (1x), respectively] under the control of the murine PrP promoter in a murine
Prnp0/0 background which were generated and characterized in a similar way as described pre-
viously [73], were prepared also as previously described [10]. Briefly, perfused whole brains,
were homogenized at 10% (w/v) in CB with protease inhibitor cocktail (Roche) in a glass pot-
ter pestle (Fisher scientific), aliquoted and stored at -80˚C until required.
Brain-PMCA was performed based on modified versions of the PMCA described previously
[74–76], to estimate the potential in vivo infectivity of the recombinant seeds generated prior
to bioassays [10]. Using TgVole (4x) or TgVole (1x) brain homogenates as substrates, seeded
at 1:10 dilution for the first 24 h round of PMCA, in a S-4000 Misonix sonicator with micro-
plate system (Qsonica) with incubation cycles of 30 min followed by sonication pulses of 20 s
at 80% power at 38˚C regulated by a circulating water bath. To avoid cross-contamination, all
PMCA tubes were sealed with plastic film (Parafilm) prior to introduction in the bath sonica-
tor to prevent accidental opening. For serial rounds of PMCA, the product of the previous
round was diluted 1:10 in fresh substrate and another 24 h round of PMCA performed under
identical conditions. After each round of PMCA, the external surfaces of all the tubes were
cleaned thoroughly with sodium hypochlorite and tubes containing different seeds or from
different experiments were treated separately. 1 mm zirconium silicate beads (BioSpec Prod-
ucts) were included in each reaction to favor the reproducibility of the results [77]. Unseeded
controls were included together with all the seeded samples subjected to brain-PMCA. Propa-
gation was determined by PK-digestion of the PMCA products followed by Western blotting.
recPMCA was performed as described previously [9, 71, 72, 78] using a Q-700 Misonix
sonicator with microplate system (Qsonica) with incubation cycles of 30 min, followed by son-
ication pulses of 15–20 s at 60–80% power at 37–39˚C regulated by a circulating water bath.
To determine the propagation capacity of each recombinant seed they were diluted serially
1:10 in recombinant PrP-based substrate containing recombinant bank vole I109 PrP comple-
mented with dextran sulfate. Dilutions from 10−1 to 10−7 were subjected to a single 24 h round
of recPMCA. Again, all the PMCA tubes were sealed with plastic film prior to introduction in
the bath sonicator to prevent accidental opening and 1 mm zirconium silicate beads (BioSpec
Products) were added to favor the reproducibility of the results [77].
PMSA was performed using rec-PrP derived substrates complemented with dextran sulfate.
Initially the temperature was set at 38˚C using a Thermomixer (Eppendorf) with internal tem-
perature control or a shaker (Monoshake, Thermo Scientific) placed inside an incubator
(Nahita) and shaking at 700 rpm set to 60 s of shaking and 5 min incubation cycles for 24 h
propagation rounds unless indicated otherwise. With the same substrates and tubes used for
recPMCA and the addition of 1 mm zirconium silicate beads, serial rounds at 1:10 to 1:1,000
dilutions (up to 30 rounds) and serial seed dilutions (from 10−1 to 10−8) in single 24 h rounds
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were performed. After optimization, all PMSA reactions were performed at 39˚C and 1,000
rpm in a continuous mode.
Preparation of fibrillary bank vole rec-PrP in the presence of urea
The preparation of non-infectious fibrillary bank vole rec-PrP was performed following the
protocol reported previously [79]. Briefly, recombinant bank vole PrP (120 μM in 6 M Gnd-
HCl) was diluted to a final concentration of 20 μM in 20 mM sodium acetate buffer (pH 5)
and dialyzed against 10 mM sodium acetate (pH 5). The dialyzed protein was incubated in 1
M Gnd-HCl, 3 M urea and 150 mM of NaCl in PBS (pH7) at 37˚C and continuous shaking
(600 rpm) for 72 h. Fibril formation was monitored using Thioflavin T.
Biochemical characterization of in vitro- and in vivo-generated prion
strains
Protease K digestion: recPMCA products based on Prnp0/0 complemented substrates were
digested by mixing the sample with N-Lauroylsarcosine sodium salt (sarkosyl) (Sigma-
Aldrich) 10% in PBS 1:1 (v/v) and adding proteinase K (PK) (Roche) at 85 μg/ml for 1 h at
42˚C and shaking at 450 rpm as described previously [9]. Digestion was stopped by addition of
loading buffer 1x (NuPage LDS, Invitrogen). For recPMCA and PMSA products, comple-
mented with dextran sulfate, digestion was exactly the same but with 25 μg/ml of PK. For Blue-
Safe staining, 500 μl of dextran complemented PMSA or recPMCA products were digested
without any additional buffer at 25 μg/ml of PK for 1 h at 42˚C and shaking at 450 rpm. After
digestion samples were immediately centrifuged at 19,000 g at 4˚C for 15 min, the supernatant
was discarded and the pellet resuspended and washed with 700 μl PBS. After a further 5 min at
19,000 g at 4˚C, the supernatant was discarded and the washed pellet resuspended in 15 μl of
loading buffer 1x (NuPage LDS, Invitrogen). In occasional cases other PK concentrations were
used and indicated. For brain-derived samples, both obtained from diseased animals and
brain-PMCA, samples were mixed 1:1 (v/v) with a digestion buffer containing 2% Nonidet
P40 (Sigma-Aldrich), 2% Tween-20 (Sigma-Aldrich) and 5% sarkosyl in PBS and digested at
85 μg/ml for 1 h at 42˚C and shaking at 450 rpm. Digestion was stopped by addition of loading
buffer 1x (NuPage LDS 1X, Invitrogen).
PK-resistant PrP detection: for total protein detection, PK-digested and concentrated sam-
ples in loading buffer were boiled for 10 min at 100˚C and loaded onto 4–12% acrylamide gels
(NuPAGE Midi gel, Invitrogen Life Technologies) and subjected to electrophoresis for 1 h and
20 min (10 min at 70 V, 10 min at 110 V and 1 h at 150 V) and stained with BlueSafe (NZY-
Tech) for 1 h at room temperature. For prion protein immunodetection, Western blotting was
performed as described previously [78]. Briefly, PK-digested samples were boiled for 10 min
and loaded on 4–12% acrylamide gels (NuPAGE Midi gel Invitrogen Life Technologies), sub-
jected to electrophoresis for approximately 1 h and 20 min and transferred to a PVDF mem-
brane (Trans-Blot Turbo Transfer Pack, Bio-Rad) using the Trans-Blot Turbo transfer system
(Bio-Rad). After blocking non-specific antibody binding of the membranes by incubation in
5% non-fat milk powder for 1 h at room temperature, monoclonal antibodies 12B2 (1:2,500),
D18 (1:5,000) or Saf83 (1:400) were added at the indicated dilutions and incubated for 1 h at
room temperature, prior to washing, incubation with peroxidase-conjugated secondary anti-
mouse antibody (m-IgGκ BP-HRP, Santa Cruz Biotechnology) or goat anti-human IgG (H+L,
Thermo Scientific) and developed with an enhanced chemiluminescent horseradish peroxi-
dase substrate (West Pico Plus, Thermo Scientific).
Epitope mapping: the characterization of misfolded recombinant PrP fragments resulting
from PK digestion by epitope mapping was performed using the same protease digested
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sample (25 μg/ml for 1 h at 42˚C and shaking at 450 rpm) processed for BlueSafe staining and
same amount loaded in multiple lanes of 4–12% acrylamide gels. After checking that each lane
contained the same amount of protein by BlueSafe staining, the gel was transferred to a PVDF
membrane (Trans-Blot Turbo Transfer Pack, Bio-Rad) using the Trans-Blot Turbo transfer
system (Bio-Rad). The membranes were blocked to prevent non-specific antibody binding in
5% non-fat milk powder for 1 h at room temperature, individual lanes were cut and incubated
separately with the following antibodies: 12B2 (1:2,500), 9A2 (1:4,000), 7D9 (1:1,000), D18
(1:5,000), Saf83 (1:400), Sa84 (1:400) and POM19 (1:10,000).
ESI-TOF: for mass spectrometry-based analysis of PK-resistant fragments of L-seeded-
PMSA, the pellet from 2 ml of PK-treated sample was resuspended in 70 μl of 6M Guanidine-
HCl by 3 pulses of tip sonication and incubated at 37˚C for 1 h. Trifluoracetic acid was then
added to a final concentration of 1%. 4 μl of the sample were injected into a micro liquid chro-
matography system (Eksigent Technologies nanoLC 400, SCIEX) coupled to high speed Triple
TOF 6600 mass spectrometer (SCIEX) with a micro flow source. The sample was injected to a
YMC-TRIART C18 trap column (YMC Technologies, Teknokroma) with a 3 mm particle size
and 120 Å pore size. The loading pump delivered a wash solution of 0.1% formic acid in water
at 10 μl/min. Then the sample was eluted and fed into a silica-based 150 × 0.30 mm, 3 mm par-
ticle size and 120 Å pore size Chrom XP C18 reversed phase analytical column (Eksigent,
SCIEX) by a micro-pump operating at 5 μl/min and applying a gradient consisting of 0.1% for-
mic acid in water as mobile phase A, and 0.1% formic acid in acetonitrile as mobile phase B.
Peptides were separated using a 40 min gradient ranging from 2% to 90% mobile phase B
(mobile phase A: 2% acetonitrile, 0.1% formic acid; mobile phase B: 100% acetonitrile, 0.1%
formic acid). TOF MS data were acquired in a TripleTOF 6600 System (SCIEX, Foster City,
CA) using the following parameters; source and interface conditions were ion spray voltage
floating (ISVF) 5500 V, curtain gas (CUR) 25, collision energy (CE) 10 and ion source gas 1
(GS1) 25. Finally, the protein was reconstructed using the Bio tool integrated algorithm. Data
were deconvolved using a m/z range of 350–1400.
Evaluation of size distribution of aggregates by sedimentation velocity analysis in continuous
sucrose gradient: Based on experiments performed previously [55], adapted to the recombinant
samples devoid of any material but 5% (w/v) dextran sulfate, 1% (w/v) Triton-X-100 and 0.15
M NaCl. A wide range continuous sucrose gradient was prepared from 10% (top) to 80% (bot-
tom) (w/v) expecting large aggregates and using a total volume of 12.5 ml in order to achieve a
good resolution in case of high heterogeneity of aggregate size. The gradient was prepared by
diffusion of a discontinuous gradient that included 2.5 ml layers of 80-60-40-20 and 10% (w/v)
sucrose solutions with 0.2% of sarkosyl to favor correct partition of weakly interacting PrP spe-
cies. The discontinuous gradient, prepared on ultra-clear centrifuge tubes (14x89 mm, Beck-
man Coulter) sealed with parafilm, were carefully rotated to horizontal position and incubated
overnight at 4˚C before loading the sample. Immediately before ultracentrifugation, 2.5 ml
from the top were replaced by 2.5 ml of either PK-digested (85 μg/ml for 1 h at 42˚C) or undi-
gested L-seeded-PMSA and centrifuged at 40,000 rpm (approximately 200,000 g) for 18 h in a
swinging-bucket SW-41 rotor using an Optima ultracentrifuge (Beckman Coulter). After cen-
trifugation, 500 μl fractions were manually collected from top to bottom and pellet also resus-
pended in 500 μl and processed as follows for western blotting: 4 μl of each fraction of the
undigested sample was diluted in 16 μl of PBS and 10 μl of NuPage 4X loading buffer, loading
15 μl from this mix in the gel. 200 μl of each PK-digested sample fraction were precipitated
with methanol, resuspended in 30 μl of 1:3 PBS and NuPage 4X buffer from which 10 μl were
loaded. Thus, approximately 30 times more sample was loaded for PK-digested sample with
respect to undigested sample. Western blot was performed as described in previous sections
and developed with Saf83 mAb (1:400).
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Biological characterization of in vitro generated prion strains
Preparation of in vivo and in vitro derived inocula: 10% brain homogenates from vole-adapted
chronic wasting disease (CWD) were diluted 10−1 in sterile PBS prior to intracerebral inocula-
tion into TgVole (1x) and bank voles 109I (Bv109I). Equally, PMCA and PMSA products were
diluted 10−1 in sterile PBS prior to intracerebral inoculation in the same models. The protease-
resistant rec-PrP amount, estimated by Western blotting, was comparable in all samples. The
inocula for the second passage were prepared, as 10% (w/v) brain homogenates in PBS form
the first passage animals.
Animal inoculations: groups of eight-week-old bank voles (Bv109I) were inoculated intrace-
rebrally with 20 μl of homogenate into the left cerebral hemisphere using a sterile disposable
27-gauge hypodermic needle while under ketamine anesthesia (ketamine 0.1 μg/g). Groups of
5 to 10 TgVole (1x) animals were inoculated in the same way but using tribromoethanol
(Avertin) (0.5 mg/g) as anesthetic. The animals were examined twice a week until neurological
clinical signs appeared, after which they were examined daily. Clinically affected animals were
culled at the terminal stage of the disease, but before neurological impairment compromised
their welfare, by exposure to a rising concentration of carbon dioxide. Survival time was calcu-
lated as the interval between inoculation and culling or death. Post-mortem, the brain was
removed and divided sagitally to be stored at -80˚C and fixed in formalin.
Neuropathology: histology and immunohistochemistry were performed on formalin-fixed
tissues as described previously [80]. Briefly, brains were trimmed at standard coronal levels,
dehydrated through graded alcohols, embedded in paraffin wax, sectioned (6 μm) and stained
with hematoxylin and eosin. Immunohistochemistry for PrP was performed using the 6C2
mAb (1:300) as described previously [81].
Preparation of recombinant prions for structural studies
Large volumes of PMSA products for structural studies, such as solid state Nuclear Magnetic Res-
onance (ssNMR), were generated in 5 ml tubes (Eppendorf) at optimized PMSA conditions and
the resulting products were digested using 25 μg/ml of PK for 1 h at 42˚C and centrifuged imme-
diately at 19,000 g for 1 h at 4˚C. The pellets were washed with PBS and centrifuged again at
19,000 g for 15 min at 4˚C. The supernatants were discarded and the pellet resuspended in water.
Solid state Nuclear Magnetic Resonance
For MAS NMR measurements, the sample was sealed hermetically in a custom-built unbreak-
able polyformaldehyde rotor insert designed to fit into 3.2 mm Varian rotors. The 13C NMR
signal of this material at 89.1 ppm does not interfere with the protein spectra [82]. Solid-state
NMR spectra were recorded using a 3.2 mm MAS probe head in double resonance mode
(1H,13C) at a static magnetic field of 14.1 T (Varian) and a MAS frequency of 11 kHz ± 3 Hz, at
a nominal temperature of 0˚C (temperature of the cooling gas). The 1H 90˚ pulse length was
3 μs, the 13C 90˚ pulse length 6.5 μs. The Proton-driven spin-diffusion (PDSD) experiment
was recorded with a longitudinal mixing time of 50 ms, during indirect evolution and detec-
tion SPINAL-64 proton decoupling [83] at an rf field strength of 83 kHz. 196 complex points
were recorded in the indirect dimension, corresponding to a maximum t1 acquisition time of
6 ms. In total five spectra with 128, 176 and 3�320 scans were recorded and summated, such
that the total number of scans was 1,264. The 2D spectrum was processed using the squared
cosine window functions in both dimensions and referenced to DSS by using adamantane as
an external reference. A control INEPT spectrum, which exclusively displays signals of highly
mobile protein regions, was recorded with 400 scans at a nominal temperature of 15˚C, but no
signals were visible [47].
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Ethics statement
TgVole mice were obtained from the breeding colony at CIC bioGUNE (Spain) and were
inoculated at the University of Santiago de Compostela. All experiments involving animals
in Spain adhered to the guidelines included in the Spanish law “Real Decreto 1201/2005 de
10 de Octubre” on protection of animals used for experimentation and other scientific pur-
poses, which is based on the European Directive 86/609/EEC on Laboratory Animal Protec-
tion. The project was approved by the Ethical Committees on Animal Welfare (project codes
assigned by the Ethical Committee P-CBG-CBBA-0314 and 15005/16/006) and performed
under their supervision. Bank voles were obtained from the breeding colony at the Istituto
Superiore di Sanità (ISS), Italy. Experiments involving animals followed the "Principles of
laboratory animal care" (NIH publication No. 86–23, revised 1985) as well as the guidelines
contained in the Italian Legislative Decree 116/92, which is based on the European Directive
86/609/EEC on Laboratory Animal Protection, and then in the Legislative Decree 26/2014,
which transposed the European Directive 2010/63/UE on Laboratory Animal Protection.
The research protocol was performed under the supervision of the Service for Biotechnology
and Animal Welfare of the ISS and was approved by the Italian Ministry of Health (decree
number 84/12.B).
Supporting information
S1 Fig. Shaking system and ad hoc designed racks for different tube sizes. Photograph on
the left shows the rack designed with 96 wells for 0.2 ml PCR tubes on the shaker used for
PMSA reactions. The photograph on the right shows the rack with 6 horizontal cells for 5 ml
tubes suitable for the same shaker. Both racks were designed ad hoc and 3D-printed (I+3D).
Racks for any desired tube can be designed and printed making PMSA a highly versatile
method for misfolded protein production.
(PDF)
S2 Fig. PrP expression levels in TgVole (1x) animals compared to PrP expression levels of
bank vole I109 by Western blot. 10% brain homogenates from TgVole (1x) (I109I) mouse
and bank vole 109I were diluted 1:16, 1:32, 1:64 and 1:128 and analyzed by Western blot using
monoclonal antibody D18 (1:5,000). The PrP expression levels of TgVole (1x) were equal to
PrPC levels in bank vole brain based on signal intensity. No significant differences were
observed in the electrophoretic migration patterns. Mw: Molecular weight.
(PDF)
S3 Fig. Sedimentation velocity analysis of L-seeded-PMSA by ultracentrifugation through
a continuous sucrose gradient. Proteinase K-digested and undigested L-seeded-PMSA were
subjected to ultracentrifugation at ~200,000 g through a continuous sucrose gradient ranging
from 10 to 80% (w/v) with 0.2% sarkosyl to determine the size distribution of total PrP and
PrPres assemblies by Western blot. The equivalent of 2 μl of each fraction of the gradient were
loaded for the undigested sample, while for PK-digested sample, fractions were precipitated
with methanol loading the equivalent to 60 μl, thus PK-digested gel shows 30-fold higher sam-
ple amount than the gel of undigested fractions. Briefly, the sedimentation pattern shows total
absence of monomeric PrP in the top fractions and a continuum in the aggregate size from
fractions containing around 30% to 80% sucrose for the untreated sample and from around
40% to 80% sucrose for the PK-digested sample, suggesting predominance of large PK-resis-
tant assemblies in the sample. This indicates the presence of a heterogeneous size assemblies
but does not reveal clearly different majoritarian populations that could point towards the exis-
tence of distinct assembly types regarding tertiary structure. Developed with Saf83 mAb
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(1:400). PK: Proteinase K, MW; molecular weight marker.
(PDF)
S1 Table. L-seeded-PMSA protease K-resistant fragments identified by ESI-TOF.
(PDF)
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